Navigation Links
Oncothyreon reports first quarter 2009 financial results
Date:5/14/2009

in 2009.

As of March 31, 2009, Oncothyreon's cash and cash equivalents were $15.4 million, compared to $19.2 million at the end of 2008, a decrease of $3.8 million, or 19.8 percent. Major contributors to the net change included $2.1 million used in operations in the quarter and a decrease in accounts payable and accrued liabilities of $1.7 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

Expenses in 2009 are expected to be substantially less than in 2008, primarily as a result of transferring manufacturing and process development activities for Stimuvax to Merck KGaA and of the previously announced plan to restrict development activities to PX-478 and PX-866. Oncothyreon currently expects cash used in operations in 2009 to be approximately $12 million. As a result, Oncothyreon estimates that the Company's existing cash, together with a milestone payment from Merck KGaA expected at year end, will be sufficient to fund operations for at least the next twelve (12) months.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of hi
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon regains compliance with NASDAQ listing requirements
2. Oncothyreon to present at Invest Northwest 2009
3. Oncothyreon reports full year and fourth quarter 2008 financial results
4. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
5. Oncothyreon to present at BIO CEO & Investor Conference 2009
6. Oncothyreon reports third quarter 2008 financial results
7. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
8. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
9. Oncothyreon to present at BIO Investor Forum 2008
10. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
11. Oncothyreon announces prioritization plan for development programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... GLEN BURNIE, Md. , Aug. 19, 2014 /PRNewswire/ ... the clinical research industry, recently announced the formation of ... is pleased to announce the addition of Dr. ... Photo - http://photos.prnewswire.com/prnh/20140818/136957 ... insight across a variety of therapeutic areas and set ...
(Date:8/19/2014)... 2014 Sales Horizons, a leader in ... online sales skills training course to help companies ... clinical staff spend the majority of their time on ... center, or physician practice – providing support and education ... there? Sales Horizons believes clinical staff are and should ...
(Date:8/18/2014)... Aug. 18, 2014 BioElectronics Corporation ... consumer medical devices said that its EVP ... by CEOLIVE.TV as part of its Executive ... is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... to investors the unique advantages of BioElectronics ...
(Date:8/18/2014)... NEW YORK , August 18, 2014 /PRNewswire/ ... report published by Transparency Market Research "Life Science ... Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents ... Research and Academic Institutions, Clinical Laboratories, and Forensic ... and Forecast, 2013 - 2019", the global life ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5
... BPUR ) today announced its financial results for ... quarter, the company reported a net,loss of $5.8 million, ... loss,of $6.9 million, or $0.53 per common share, for ... on January 31, 2008 and 2007 were,34,971,087 and 15,543,025, ...
... on March 13, 2008 at 9:00 am (Eastern) ... / 6:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong), ... Inc. (NYSE: WX ) ("WuXi PharmaTech" or "the ... company, today announced that it will release unaudited,financial results ...
... Sweden, February 21 With two successful,international ... a new expansion phase. The share issue ... number of significant product,launches in 2008-2009. These ... leading global pharmaceutical companies to meet the,industry,s ...
Cached Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008 2
(Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
(Date:8/19/2014)... Can nutrition rating systems be used in supermarkets to ... University researchers sought to answer that very question by ... uses the Guiding Stars System to rate the nutritional ... Cornell Food and Brand Lab,s David Just, PhD, and ... studied the sales records of over 150 Hannaford Supermarkets ...
(Date:8/19/2014)... not a lemur. It,s not an African Bush Baby or ... adorable and downright "cool" primate from Southeast Asia. , "It,s ... said Rafe Brown, curator-in-charge at the University of Kansas, Biodiversity ... cute, furry body; a long tail with a furry tuft ... that look a bit like the disks on the digits ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... American eels are fast disappearing from restaurant menus as ... the reasons for the eel decline remain as mysterious ... NOAA scientist and colleagues in Japan and the United ... primary factor in declining reproduction and survival rates. ...
... Matyjaszewski have created a version of Harry Potters famed invisibility cloak for ... Through a collaborative effort, ... developed a new design paradigm that makes particles invisible. , ... In a recent edition of Advanced ...
... cancer immune therapy have made an unexpected find: They,ve ... inflammatory bowel disease (IBD), a cluster of conditions that ... and diarrhea. , The two most common forms ... in extreme cases, they can be fatal. The mouse ...
Cached Biology News:Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 2Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 3Carnegie Mellon researchers create invisibiity cloak 2Scientists successfully treat new mouse model of inflammatory bowel disease 2
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... The Jouan RCT series of refrigerated cold ... to trapping of low volatility/aqueous solvents or ... RC10 and other vacuum concentrators/centrifugal evaporators. Also ... cooling systems such as used in electron ...
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Biology Products: